問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

  • 0

    Total Beds

  • 0

    Total Doctors

  • 235New Taipei CityJhonghe

Recruiting Trial

230Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

435Cases

2017-08-01 - 2020-04-30

Phase III

A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease

  • Condition/Disease

    mild to moderate Alzheimer's disease patient

  • Test Drug

    Donepezil transdermal patch

Participate Sites
12Sites

Terminated12Sites

楊淵韓
Kaohsiung Municipal Ta-Tung Hospital

Division of Neurology

2015-04-15 - 2020-09-30

Phase I

An Open-Label Study to Assess the Safety and Tolerability of Active Immunotherapy with Escalating Doses of OBI-833/OBI-821 (Globo H-CRM197/Adjuvant) in Subjects with Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Condition/Disease

    Metastatic Gastric, Lung, Colorectal or Breast Cancer

  • Test Drug

    OBI-833 (Globo H-CRM197)/OBI-821

Participate Sites
4Sites

Recruiting4Sites

李凱靈
Taipei Medical University Hospital

Division of Hematology & Oncology

2022-03-01 - 2022-09-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

2014-05-01 - 2017-12-31

Phase III

A Multi-center, Randomized, Double-Blind, Double-Dummy, parallel, Controlled, Phase III Clinical Trial Evaluating the Efficacy and Safety of Nemonoxacin Malate Sodium Chloride Injection versus Levofloxacin Sodium Chloride Injection in the Treatment of Adult Community-Acquired Pneumonia.

  • Condition/Disease

    Adult Community-Acquired Pneumonia

  • Test Drug

    Nemonoxacin Malate Sodium Chloride

Participate Sites
17Sites

Terminated17Sites

2015-03-01 - 2016-10-26

Phase II

A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.

  • Condition/Disease

    Hepatitis C

  • Test Drug

    TG-2349

Participate Sites
9Sites

Terminated9Sites

鄭斌男
National Taiwan University Hospital

Division of General Internal Medicine

2016-01-01 - 2019-12-31

Phase IV

A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration with Nemonoxacin in Treating Elderly Patients with Community-Acquired Pneumonia

  • Condition/Disease

    h Community-Acquired Pneumonia

  • Test Drug

    Taigexyn

Participate Sites
9Sites

Terminated9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2012-07-01 - 2019-08-31

Phase II/III

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Condition/Disease

    A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Test Drug

    Isoniazid tablet formulated with excipient HUEXC030

Participate Sites
13Sites

Terminated13Sites

2011-10-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

1 40 41 42 43 44
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB